
|Videos|February 13, 2016
Dr. James L. Gulley on Treatment Beyond the Second Line in Bladder Cancer
Author(s)James L. Gulley, MD, PhD
Gulley says there is no standard procedure for the third line setting in bladder cancer, and that most oncologists would either turn to single-agent chemotherapy or to clinical trials.
Advertisement
James L. Gulley, MD, PhD, chief of the Genitourinary Malignancies Branch, director of Medical Oncology Service, National Cancer Institute, discusses treatment beyond the second line in bladder cancer. Gulley says there is no standard procedure for the third line setting in bladder cancer, and that most oncologists would either turn to single-agent chemotherapy or to clinical trials.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Talquetamab Shows Durable Responses in R/R MM at 3-Year Follow-Up
2
Cost-Effectiveness of Perioperative Pembro in Head and Neck Cancer Hinges on PD-L1 Expression
3
FDA Does Not Approve 177Lu-Edotreotide for GEP-NETs
4
Dr Lonial on Using MRD Negativity to Guide Maintenance Discontinuation in Myeloma
5







































